Collaboration is key to advancing cell therapy researchDr. Anne Kerber, VP, Head of Clinical Development, Europe at Kite, a Gilead Company, explains how the company Share XCollaboration is key to advancing cell therapy researchhttps://pharmaphorum.com/r-d/collaboration-is-key-to-advancing-cell-therapy-research/
Gilead’s Trodelvy approved in metastatic urothelial cancerGilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Share XGilead’s Trodelvy approved in metastatic urothelial cancerhttps://pharmaphorum.com/news/gileads-trodelvy-approved-in-metastatic-urothelial-cancer/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Gilead pushes on with NASH partnership with Novo NordiskGilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH – Share XGilead pushes on with NASH partnership with Novo Nordiskhttps://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/
Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
Veklury rescues Gilead from COVID doldrums in Q4Gilead’s COVID-19 drug Veklury (remdesivir) is helping the company through disruption caused by the pandemic and patent expiry Share XVeklury rescues Gilead from COVID doldrums in Q4https://pharmaphorum.com/news/veklury-rescues-gilead-from-covid-doldrums-in-q4/
NICE backs broad use for Gilead/Galapagos arthritis pill JyselecaPatients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ Share XNICE backs broad use for Gilead/Galapagos arthritis pill Jyselecahttps://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/
NHS and Kite sign access deal for Kite’s cancer cell therapy TecartusNHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell Share XNHS and Kite sign access deal for Kite’s cancer cell therapy Tecartushttps://pharmaphorum.com/news/nhs-kite-cancer-therapy/
High hopes as Inventiva takes NASH contender into phase 3Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, Share XHigh hopes as Inventiva takes NASH contender into phase 3https://pharmaphorum.com/news/high-hopes-as-inventiva-takes-nash-contender-into-phase-3/
